Novabay Pharmaceuticals Inc’s recently made public that its 10% Owner POPLAR POINT CAPITAL PARTNERS acquired Company’s shares for reported $12929.0 on Apr 03 ’25. In the deal valued at $0.56 per share,22,976 shares were bought. As a result of this transaction, POPLAR POINT CAPITAL PARTNERS now holds 1,015,462 shares worth roughly $3.79 million.
Then, POPLAR POINT CAPITAL PARTNERS bought 4,538 shares, generating $2,367 in total proceeds. Upon buying the shares at $0.52, the 10% Owner now owns 1,020,000 shares.
Before that, POPLAR POINT CAPITAL PARTNERS bought 917 shares. Novabay Pharmaceuticals Inc shares valued at $532 were divested by the 10% Owner at a price of $0.58 per share. As a result of the transaction, POPLAR POINT CAPITAL PARTNERS now holds 992,486 shares, worth roughly $3.7 million.
Ladenburg Thalmann initiated its Novabay Pharmaceuticals Inc [NBY] rating to a Buy in a research note published on September 18, 2019; the price target was $1.10. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in early July has reiterated a ‘”a Buy”‘ rating for it. Laidlaw also remained covering NBY and reiterated its “Buy” recommendation on November 15, 2017. ROTH Capital started covering the stock on June 05, 2017. It rated NBY as “a Buy”.
Price Performance Review of NBY
On Friday, Novabay Pharmaceuticals Inc [AMEX:NBY] saw its stock fall -11.61% to $3.73. Over the last five days, the stock has gained 126.06%. Novabay Pharmaceuticals Inc shares have risen nearly 669.71% since the year began. Nevertheless, the stocks have risen 520.63% over the past one year. While a 52-week high of $4.44 was reached on 09/04/25, a 52-week low of $0.44 was recorded on 04/08/25.
Levels Of Support And Resistance For NBY Stock
The 24-hour chart illustrates a support level at 3.27, which if violated will result in even more drops to 2.82. On the upside, there is a resistance level at 4.07. A further resistance level may holdings at 4.42.
How much short interest is there in Novabay Pharmaceuticals Inc?
A steep rise in short interest was recorded in Novabay Pharmaceuticals Inc stocks on 2025-08-15, growing by 38036.0 shares to a total of 76296.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 38260.0 shares. There was a rise of 49.85%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 27, 2017 when Laidlaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
